 - Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with dabrafenibtrametinib, breastfeeding should be discontinued prior to treatment with dabrafenibtrametinib. These potential risks may also apply to other agents used in this study. 